MET and non-small cell lung carcinoma: Crizotinib, capmatinib, and tepotinib are suggested for the treatment of patients with high-level MET-amplified NSCLC [45] or MET exon 14 skipping, and other new combinations or novel therapeutic agents are currently under investigation [2,43].